Avax Technologies

Avax Technologies, Inc.
Company typePublic
Expert Market: AVXT
IndustryBiomedicine
Headquarters
Philadelphia, Pennsylvania
,
United States
Key people
Richard Rainey (chairman and CEO)
ProductsAC Vaccine
ServicesCancer vaccines
SubsidiariesGenopoietic SA

Avax Technologies, Inc. is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR).

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.